Member Info for Laura2022

Top lock

Youve bought but also think that ?

Seems counter intuitive

Its going to be wiped out with a rights issue or something even worse

Hopefully debull is happy

Every.one of his recent posts showed a level of worry, but as an apparent long term holder he surely must happy with PYC being at 15mth High

£1mln x 2

Top lock

Trench and KingHomer offer much better insight

Great end to the week

Up over 100% since start of Feb

Late into afternoon

Rose

Tony

Why the constant new IDS?

Sorry £5000

2437 shares

Ive added another £4000

See sky news 2 week's ago

£3.50 stated

Leaky value

Wow

These were correct as of early Jan2026

Peer comparisons on revenue v mkt cap

APTA £35mln cap and £1.2mln full year revs( = x 30 annual rev)

FAB £17 mln and £1.96mln full year  x 9

PYC £0.85mln  and £0.85mln full year which was 40% growth ( x 1)

GENI (£10mln) revenues £1.6mln, losses £2.4

Last weekend before potential offers

Thanks BTF

Those assets aren't much use though when swamped with debt

Been watching for 9mths+

Best wishes ,

Toplocks

If helps

record order book

* Recently  booked a further amount of revenues for contracts to be completed Dec 2025

*recently awarded options at 40:, 170% and 350% premiums to current share price , with focus on next step for company of "cash generation "

Key growth in all areas , particularly bio statistics, company very pleased and very confident about the niche growth markets many of which are now mandatory under EU law and most could well become mandatory for drug design. Positive regulatory environment eg FDA

[  ] Key market drivers

* model informed discovery/bio stats help

> costs $2.5bln and 10-15yrs to get drug to market and less than 5% success rate - PYC modelling drastically cuts this and using MMID/BS can

1) save $100-500mln

2) increase to 20-30% success at Phase II

3) 30-50% fewer patients

[  ] Key growth/CAGR markets which PYC operate

MMID 18% CAGR with market set to be $13bln

Bio Statistics  24% CAGR $40bln market

Regulatory authorities across the world require robust biometrics practices to approve new drugs. Biometrics typically incorporates three main areas:

1. Biostatistics: Supporting the design of clinical studies and analysis of resulting data

2. Statistical Programming: Use of programming language to process, analyse and visualise clinical data

3. Data Management: Setup and oversight of the collection, entry, and validation of clinical trial data

Personalised medicine 7.5% CAGR and largest market is North America ( partner DoseMeRx based there)

General overviews

Total Income at 3yr high and bolstered by moving into new therapeutic areas such as immunology and cardiovascular

Still only valued at 1.5 x estimated 2026 revenues

Ridiculously undervalued

Debt (£400mln) now x 10 the market cap

Won't end well

[ ] Key market drivers

* model informed discovery/bio stats help

> costs $2.5bln and 10-15yrs to get drug to market and less than 5% success rate - PYC modelling drastically cuts this and using MMID/BS can

1) save $100-500mln

2) increase to 20-30% success at Phase II

3) 30-50% fewer patients

[ ] Key growth/CAGR markets which PYC operate

MMID 18% CAGR with market set to be $13bln

Bio Statistics 24% CAGR $40bln market